Pfizer study shows safety of switching to Inflectra therapy

Pfizer has announced the findings of a new clinical trial that further demonstrates the effectiveness of Inflectra, its biosimilar Crohn's disease therapy.

The company has reported 54-week results from a study that has shown that patients who switch to Inflectra from Remicade – the branded therapy on which Inflectra is based – are able to do so without any drop-off in performance.

Switching patients with Crohn's disease to Inflectra from Remicade led to comparable efficacy, safety and tolerability to sustained treatment with Remicade over a 54-week period, while the biosimilar was also shown to be well-tolerated, with a similar safety profile to Remicade.

These findings add to a well-established body of evidence, including real-world studies and the NOR-SWITCH trial, showing that switching stable patients to Inflectra can be a beneficial option.

Dr Sam Azoulay, senior vice-president and chief medical officer at Pfizer Essential Health, said: "Today's announcement further highlights Pfizer's commitment to biosimilars and provides additional evidence supporting use of Inflectra in Crohn's disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.